Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 9/20 | 0.62 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | HTR7 | P34969 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 7/20 | 0.41 |
| ▸ | LMNA | P02545 | 5/20 | 0.41 |
| ▸ | TP53 | P04637 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4026117 | 0.82 | HTR6 (0.55) | HTR6 | |
| SCHEMBL1590308 | 0.77 | HTR6 (1.00) | HTR6MAPTPOLB | |
| SCHEMBL12316100 | 0.76 | HTR2C (0.56) | HTR6HTR1AHTR2CHTR7MAPT | |
| SCHEMBL4028239 | 0.76 | HTR6 (0.51) | HTR6 | |
| SCHEMBL12316095 | 0.75 | HTR2C (0.55) | HTR6HTR1AHTR2CHTR7MAPT | |
| SCHEMBL12316138 | 0.75 | HTR6 (0.54) | HTR6HTR2C | |
| SCHEMBL1590132 | 0.75 | HTR6 (0.67) | HTR6HTR2CLMNATHRBPOLB | |
| SCHEMBL1590451 | 0.75 | HTR6 (0.67) | HTR6HTR2CLMNATHRBPOLB | |
| SCHEMBL4024729 | 0.75 | HTR6 (0.56) | HTR6HTR1AHTR2CHTR7KDM4E | |
| SCHEMBL12702633 | 0.74 | HTR6 (0.73) | HTR6POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092540-A1 | SUBSTITUTED N-PHENYL-2,3-DIHYDROIMIDAZO[2,1-B]THIAZOLE-5-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-04-21 | — | — | US | disclosed |
| US-20110092540-A1 | SUBSTITUTED N-PHENYL-2,3-DIHYDROIMIDAZO[2,1-B]THIAZOLE-5-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-04-21 | — | — | US | disclosed |
| US-20110092540-A1 | SUBSTITUTED N-PHENYL-2,3-DIHYDROIMIDAZO[2,1-B]THIAZOLE-5-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092540-A1 | SUBSTITUTED N-PHENYL-2,3-DIHYDROIMIDAZO[2,1-B]THIAZOLE-5-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS | HTR6, HTR2A, HTR4 | HTR6 1/4885HTR1A 5/4885HTR2C 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.